Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Former DEA official helped pharma company get drug quota increase, says watchdog

12/02/2021 | 01:37pm EST
FILE PHOTO: Senate Judiciary hearing on the FBI handling of the Larry Nassar investigation of sexual abuse of Olympic gymnasts, in Washington

WASHINGTON (Reuters) - A former senior official at the U.S. Drug Enforcement Administration improperly gave preferential treatment to a pharmaceutical company that was seeking a quota increase so it could manufacture more drugs, the Justice Department's internal watchdog said on Thursday.

In a one-page investigative summary, Inspector General Michael Horowitz said the unnamed official "misused" his or her official position by giving preferential treatment to the pharmaceutical company and pressured subordinates to approve the quota increase.

The increase was requested by a second unnamed former DEA official who worked for the company, the report said.

The former DEA official at the heart of the watchdog's internal probe also apparently planned to work for the pharmaceutical company upon retirement and "lacked candor" with the DEA's Office of Chief Counsel in disclosing those plans, Horowitz's report said.

"The senior DEA official misused the senior official's position at DEA by giving preferential treatment to a request by the pharmaceutical company that employed the former DEA official," the report says. "The senior DEA official pressured and directed subordinates to approve the request."

A spokesperson for the DEA did not have any immediate comment on the findings.

The inspector general's report does not identify the company at issue, or whether the former senior official ultimately went to work there.

Because the Justice Department's inspector general only has the legal authority to compel testimony from current employees, the official was able to retire and declined to voluntarily appear for questioning.

The department also declined to prosecute the official who gave preferential treatment to the drugmaker.

The DEA has come under scrutiny in recent years for its role in helping to exacerbate the ongoing U.S. opioid crisis.

The agency uses a quota system that is designed to ensure that drug manufacturers are able to produce enough drugs for medical, scientific, research and industrial needs.

The quotas apply to drugs that are deemed to be addictive, and fall into schedules I and II.

Critics have accused the DEA of failing to proactively cut the supply of painkillers manufactured in the United States by simply limiting the annual quota.

(Reporting by Sarah N. Lynch, Editing by Rosalba O'Brien)

By Sarah N. Lynch


ę Reuters 2021
Latest news "Economy & Forex"
03:20pGavilon deal to make Glencore major soy exporter in Brazil with larger U.S. foothold
RE
03:18pBank of Canada 'no hike' leaves housing fire burning, say market watchers
RE
03:15pOil falls from seven-year high as Russia tensions offset Fed tightening
RE
03:07pLebanon's jumblatt says hezbollah has main role in drug smugglin…
RE
03:03pPorn star Stormy Daniels testifies ex-lawyer Michael Avenatti 'stole from me'
RE
02:59pU.S. retail investors kept buying stocks on Fed day -analysts
RE
02:57pWall St reverses again, wiping out early gains in afternoon plunge
RE
02:56pSouthwest Airlines expects loss in Q1 after first profit in 2 years
RE
02:55pSoybeans hit 7-month high on supply worries; firm dollar sinks wheat
RE
02:55pArgentina faces billion-dollar IMF trip wire as protests simmer
RE
Latest news "Economy & Forex"